Streetbeat News

Earnings

DV

DoubleVerify Holdings (NYSE:DV) reported Q4 earnings, surpassing estimated earnings by 36% with an EPS of $0.19 against an estimate of $0.14. Revenue increased by $38.59 million from the same period last year. The company has a history of beating EPS estimates, which previously led to a 6% share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:15 pm

DUOL

Duolingo (NASDAQ:DUOL) reported Q4 earnings with a 53.0% beat on estimated EPS, reporting $0.26 versus an estimate of $0.17. Revenue increased by $47.16 million from the same period last year. The company has a history of beating EPS estimates, which previously led to a 21.0% share price increase the day after last quarter's earnings announcement.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:15 pm

MQ

Marqeta (NASDAQ:MQ) reported Q4 2023 GAAP EPS of $(0.08), meeting analyst consensus estimates. Quarterly sales reached $118.82M, surpassing the $110.65M estimate, but represented a 41.70% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:15 pm

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) reported Q4 earnings with an EPS of $0.82, significantly beating the estimate of $0.01 and marking an 8100.0% increase. Revenue rose by $138.35 million from the same period last year. The company has a history of beating EPS estimates, which previously led to a 2.0% share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:15 pm

CDNA

CareDx (NASDAQ:CDNA) reported Q4 earnings with an EPS of $-0.17, beating estimates by 37.0% but with a revenue decrease of $16.82 million from the previous year. The company has a history of beating EPS estimates, leading to a share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:15 pm

CDNA

CareDx (CDNA) reported Q4 2023 adjusted EPS of $(0.17), surpassing the $(0.27) estimate, with sales of $65.57M exceeding the $63.66M forecast. However, this represents a 20.41% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:14 pm

CRM

Salesforce Inc (NYSE:CRM) reported Q4 earnings with an 11% year-over-year revenue increase to $9.29 billion, surpassing estimates. Adjusted EPS was $2.29, beating forecasts. The company announced its first-ever cash dividend and increased its share repurchase program by $10 billion. Salesforce provided optimistic guidance for Q1 and full-year 2025, expecting to capitalize on the AI boom with its Einstein 1 Platform. Despite the positive report, CRM shares dropped 4.99% after hours.

Portfolio Pulse from Adam Eckert

February 28, 2024 | 9:14 pm

EVTC

Evertec reported Q4 adjusted earnings of $0.62 per share, missing the consensus estimate of $0.64. However, their sales of $194.62M exceeded the estimate of $179.61M, marking a 20.29% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:13 pm

SRPT

Sarepta Therapeutics (SRPT) reported Q4 2023 adjusted EPS of $0.82, significantly beating the $0.01 estimate. Quarterly sales were $396.78M, surpassing the $385.81M estimate and marking a 53.54% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:13 pm

MNST

Monster Beverage reported Q4 2023 earnings of $0.38 per share, meeting analyst estimates, but missed sales forecasts with $1.73B against the expected $1.75B, marking a 14.34% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:13 pm